Recevez
la newsletter

Actualités

UPDATE: Roche, Plexxikon In Drug Deal Potentially Worth $335 Million
By Anita Greil Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drugmaker Roche Holding AG (ROG.VX) Thursday entered an agreement with privately-held Plexxikon Inc. of the U.S. to develop and sell an experimental drug for the treatment of a rare genetic kidney disease in a deal potentially worth up to $335 million.
Roche, based in Basel, will pay Plexxikon $60 million upfront for the global rights to develop and sell a drug candidate codenamed PLX5568, as well as a number of additional undisclosed potential drug candidates.
Plexxikon could receive a further $275 million over the term of the partnership if certain milestones in the development of treatments for the disease, called polycystic kidney disease, are met, the companies said.
Plexxikon will be responsible for any discovery and early development through completion of early-stage clinical trials, including those currently being conducted for PLX5568.
The companies plan to start intermediate trials of the drug later in 2009, provided early-stage testing shows it promises to be safe and effective.
Polycystic kidney disease is a genetic disease in which cysts form in the kidneys, causing them to become progressively enlarged, ultimately leading to loss of kidney function in most patients. Currently, there are no treatments for it and patients may eventually require kidney transplantation or dialysis. In the U.S., the disease affects around 600,000 people.
At 1125 GMT, Roche shares were up CHF1.70, or 1%, at CHF171.60, in a lower Swiss market. So far this year, the stock has risen 5.6%, in line with the European healthcare stocks sector, which in times of economic uncertainty benefits from its defensive attributes.
Company Web Site: http://www.roche.com
http://www.plexxikon.com
-By Anita Greil, Dow Jones Newswires; +41 43 443 8044 ; anita.greil@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http://www.djnewsplus.com/access/al?rnd=4UlX2dQXxJ0qonPM5nmxhA%3D%3D. You can use this link on the day this article is published and the following day.

Publié le 08 janvier 2009 Copyright © 2009 Dowjones


Partager sur:


Partager sur Blogger Partager sur Delicious Partager sur Digg Partager sur Facebook Partager sur Furl Partager sur Linkedin Partager sur Myspace Partager sur Twitter Partager sur Technorati Partager sur Viadeo
CAC 40 3 707,29 Pts -0,04%

Palmarès

CREDIT AGRICO 14,05 € +3,31%
LVMH 73,03 € +2,40%
SOCIETE GENER 46,92 € +2,10%
CAP GEMINI 30,33 € -2,08%
ELECTRICITE D 37,00 € -3,19%
LAFARGE 55,82 € -3,74%
Découvrez l'offre de courtage EasyBourse

Les dernières tendances

Paris

Liste des valeurs suivies vendredi à la Bourse de Paris, où le CAC 40 a clôturé sur une note stable (-0,04% à 3.707,29 points) après une première réaction en baisse à la suite de...

Wall Street

Les valeurs américaines ont à nouveau terminé en hausse vendredi, les conseils boursiers positifs des analystes sur certaines valeurs ayant compensé l'annonce d'une aggravation du...

Tokyo

L'indice Nikkei de la Bourse de Tokyo a fini en hausse de 0,74% vendredi, les valeurs exportatrices étant confortées par les espoirs d'amélioration sur le marché de l'emploi...

Devises

Un regain d'appétit pour le risque fait légèrement reculer le dollar en Europe vendredi, tandis que le marché attend le rapport...

Pétrole

Le pétrole a terminé en hausse d'environ 1% mercredi sur le marché new-yorkais après l'annonce d'une baisse inattendue des stocks américains de brut et la fin de la réunion de la...

Taux

Le taux de chômage des Etats-Unis est à deux chiffres, pour la première fois depuis 26 ans et demi, et ce même si le rythme des pertes d'emplois a ralenti le mois...